AMGN

AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023

Retrieved on: 
Tuesday, November 7, 2023
Patient, Rheumatology Research Foundation, Standard of care, Psoriasis, Headache, American College, VAS, Diarrhea, Research, Nausea, REM, MACR, Common, Amgen, University of Washington School of Medicine, Joint, University, AMGN, American College of Rheumatology, Nonsteroidal anti-inflammatory drug, Safety, LDA, Pain, ACR, BSA, Hospital, Body surface area, Disability, Psoriatic arthritis, Pharmaceutical industry, Medical imaging, Rheumatology

THOUSAND OAKS, Calif., Nov. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla® (apremilast) in patients with early oligoarticular psoriatic arthritis. FOREMOST is the first placebo-controlled study designed to specifically assess people with oligoarticular psoriatic arthritis with early disease duration of five or fewer years. Results will be presented at the American College of Rheumatology (ACR) Convergence 2023, Nov. 10-15 in San Diego.

Key Points: 
  • Placebo
    THOUSAND OAKS, Calif., Nov. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla® (apremilast) in patients with early oligoarticular psoriatic arthritis.
  • FOREMOST is the first placebo-controlled study designed to specifically assess people with oligoarticular psoriatic arthritis with early disease duration of five or fewer years.
  • Results will be presented at the American College of Rheumatology (ACR) Convergence 2023, Nov. 10-15 in San Diego.
  • "These patients experienced a significant reduction in psoriatic disease activity, a crucial finding for those in the early stages of the condition."

AMGEN PRESENTS NEW DATA FROM PHASE 2 TRIAL OF DAZODALIBEP IN SJÖGREN'S SYNDROME AT ACR 2023

Retrieved on: 
Tuesday, November 7, 2023
EULAR, FDA, American College, Congress, Disease, Amgen, Dry, AMGN, American College of Rheumatology, Safety, Pain, Patient, ACR, CD40, Fatigue, Pharmaceutical industry, Research

THOUSAND OAKS, Calif., Nov. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from its Phase 2 study evaluating dazodalibep, an investigational medicine, for the treatment of Sjögren's. These results will be featured in presentations at the American College of Rheumatology (ACR) Convergence 2023, Nov. 10-15, in San Diego. Findings from the study demonstrate that dazodalibep may improve both the systemic and symptomatic disease burden of two different patient populations.

Key Points: 
  • THOUSAND OAKS, Calif., Nov. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from its Phase 2 study evaluating dazodalibep, an investigational medicine, for the treatment of Sjögren's.
  • These results will be featured in presentations at the American College of Rheumatology (ACR) Convergence 2023, Nov. 10-15, in San Diego.
  • Findings from the study demonstrate that dazodalibep may improve both the systemic and symptomatic disease burden of two different patient populations.
  • In May 2023, presentations at the 2023 EULAR Congress reported that at Day 169, both patient groups treated with dazodalibep achieved the study's primary endpoint.

Epidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition

Retrieved on: 
Monday, November 6, 2023
Stem cell, Genetic distance, Haematopoiesis, Peripheral artery disease, Epidemiology, Smoking, Clonal hematopoiesis, Lung cancer, Genetics, Mortality, Bone marrow, Health, Carcinoma, UK Biobank, CH, Emphysema, Genome, Disease, Risk, HSC, AMGN, Gene, Chronic obstructive pulmonary disease, Gene expression, Mutation, Cardiovascular disease, Vaccine, Amgen, Nature Genetics

Clonal hematopoiesis is a condition that arises when a single clonal lineage of hematopoietic stem cells (HSC) expands and becomes the source of a substantial proportion of mature blood cells.

Key Points: 
  • Clonal hematopoiesis is a condition that arises when a single clonal lineage of hematopoietic stem cells (HSC) expands and becomes the source of a substantial proportion of mature blood cells.
  • The study reaffirmed that clonal hematopoiesis is very common in the elderly, approaching 50% in people over 80 years old.
  • Clonal hematopoiesis has many of the hallmarks of a premalignant expansion of cell clones with a potential to become cancerous.
  • Overall, the study has provided substantial insights into the genetics and epidemiology of clonal hematopoiesis.

Epidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition

Retrieved on: 
Monday, November 6, 2023
Stem cell, Genetic distance, Haematopoiesis, Peripheral artery disease, Epidemiology, Smoking, Clonal hematopoiesis, Lung cancer, Genetics, Mortality, Bone marrow, Health, Carcinoma, UK Biobank, CH, Emphysema, Genome, Disease, Risk, HSC, AMGN, Gene, Chronic obstructive pulmonary disease, Gene expression, Mutation, Cardiovascular disease, Vaccine, Amgen, Nature Genetics

Clonal hematopoiesis is a condition that arises when a single clonal lineage of hematopoietic stem cells (HSC) expands and becomes the source of a substantial proportion of mature blood cells.

Key Points: 
  • Clonal hematopoiesis is a condition that arises when a single clonal lineage of hematopoietic stem cells (HSC) expands and becomes the source of a substantial proportion of mature blood cells.
  • The study reaffirmed that clonal hematopoiesis is very common in the elderly, approaching 50% in people over 80 years old.
  • Clonal hematopoiesis has many of the hallmarks of a premalignant expansion of cell clones with a potential to become cancerous.
  • Overall, the study has provided substantial insights into the genetics and epidemiology of clonal hematopoiesis.

AMGEN PRESENTS NEW DATA THAT SHOW BLOOD PRESSURE DECREASES FOR ADULTS TREATED WITH KRYSTEXXA® (PEGLOTICASE)

Retrieved on: 
Thursday, November 2, 2023
Week, University of Colorado, Kidney, Health, Blood pressure, Prevalence, Nephrology, Society, Chronic kidney disease, University of Colorado Denver, Division, Amgen, Methotrexate, University, AMGN, CKD, Patient, Randomized controlled trial, MIRROR, Gout, Pharmaceutical industry, Hypertension

The data will be presented at the American Society of Nephrology Kidney Week, taking place Nov. 2-5, in Philadelphia.

Key Points: 
  • The data will be presented at the American Society of Nephrology Kidney Week, taking place Nov. 2-5, in Philadelphia.
  • "Recognizing the high prevalence of hypertension among these patients, we're excited to present data that offers new insight into the potential role of urate reduction with KRYSTEXXA with methotrexate in regulating blood pressure."
  • Treatment groups had similar blood pressure prior to treatment.
  • "These new data add to prior studies and further support the potential role that both KRYSTEXXA urate-lowering and methotrexate administration played in the blood pressure changes observed."

A large international study of migraine reveals new biological pathways for treatment

Retrieved on: 
Thursday, October 26, 2023
Genetic distance, Chronic pain, Aura, FinnGen, Genetics, Intermountain Health, PRRT2, DeCODE genetics, UK Biobank, Migraine, Genome, Disease, Risk, Biology, Nature Genetics, AMGN, Gene, KCNK5, Epilepsy, Myenteric plexus, Aneurysm, Aroma compound, Vaccine, Amgen

The scientists focused on detecting sequence variants associated with the the two main subtypes of migraine: migraine with aura (often referred to as classical migraine) and migraine without aura.

Key Points: 
  • The scientists focused on detecting sequence variants associated with the the two main subtypes of migraine: migraine with aura (often referred to as classical migraine) and migraine without aura.
  • The results highlight several genes that affect one of these migraine subtypes over the other, and point to new biological pathways that could be targeted for therapeutic developments.
  • Four novel migraine with aura associations were revealed and 13 variants associated primarily with migraine without aura.
  • Of particular interest were three rare variants with large effects pointing to distinct pathologies underlying different types of migraine.

A large international study of migraine reveals new biological pathways for treatment

Retrieved on: 
Thursday, October 26, 2023
Genetic distance, Chronic pain, Aura, FinnGen, Genetics, Intermountain Health, PRRT2, DeCODE genetics, UK Biobank, Migraine, Genome, Disease, Risk, Biology, Nature Genetics, AMGN, Gene, KCNK5, Epilepsy, Myenteric plexus, Aneurysm, Aroma compound, Vaccine, Amgen

The scientists focused on detecting sequence variants associated with the the two main subtypes of migraine: migraine with aura (often referred to as classical migraine) and migraine without aura.

Key Points: 
  • The scientists focused on detecting sequence variants associated with the the two main subtypes of migraine: migraine with aura (often referred to as classical migraine) and migraine without aura.
  • The results highlight several genes that affect one of these migraine subtypes over the other, and point to new biological pathways that could be targeted for therapeutic developments.
  • Four novel migraine with aura associations were revealed and 13 variants associated primarily with migraine without aura.
  • Of particular interest were three rare variants with large effects pointing to distinct pathologies underlying different types of migraine.

AMGEN ANNOUNCES WEBCAST OF 2023 THIRD QUARTER FINANCIAL RESULTS

Retrieved on: 
Wednesday, October 25, 2023
AMGN, Internet, Calendar, Webcast, Broadcasting, Amgen

THOUSAND OAKS, Calif., Oct. 25, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Tuesday, October 31, 2023, before the opening of the U.S. financial markets.

Key Points: 
  • THOUSAND OAKS, Calif., Oct. 25, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Tuesday, October 31, 2023, before the opening of the U.S. financial markets.
  • The announcement will be followed by a conference call with the investment community at 5:00 a.m. PT.
  • Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
  • Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar.

AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER

Retrieved on: 
Sunday, October 22, 2023
Patient, Research, ESMO, Progression-free survival, Trae tha Truth, Trifluridine, DCR, Magnesium, Diarrhea, Congress, PFS, European Society for Medical Oncology, KRAS, Rash, Amgen, Research and development, Liver disease, The New England Journal of Medicine, Oncology, AMGN, ORR, Istituto nazionale per l'assicurazione contro gli infortuni sul lavoro, The Codebreakers, Pharmaceutical industry, Medical imaging, Panitumumab

THOUSAND OAKS, Calif., Oct. 22, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS® (sotorasib) (960 mg or 240 mg) in combination with Vectibix® (panitumumab). Both doses demonstrated a statistically significant superiority in progression-free survival (PFS) over the investigator's choice of therapy in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). The results are being presented today at the Presidential Symposium 2 session as a late-breaking oral presentation (LBA10) during the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain, with simultaneous publication in the New England Journal of Medicine.

Key Points: 
  • Both doses demonstrated a statistically significant superiority in progression-free survival (PFS) over the investigator's choice of therapy in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC).
  • Among secondary endpoints, higher objective response rate (ORR) and disease control rate (DCR) were observed in patients treated with LUMAKRAS plus Vectibix at both doses versus investigator's choice of care.
  • Patients at both dose regimens of LUMAKRAS plus Vectibix experienced a longer duration of treatment than those treated with investigator's choice therapy.
  • Based on the CodeBreaK 300 primary analysis results, Amgen is planning to submit these data to regulatory authorities.

AMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER

Retrieved on: 
Friday, October 20, 2023
Survival, SCLC, ESMO, Progression-free survival, Trae tha Truth, Dysgeusia, MOS, Congress, European Society for Medical Oncology, Fever, Confidence interval, Amgen, Cytokine release syndrome, The New England Journal of Medicine, Oncology, ORR, AMGN, CRS, DLL3, Patient, Prognosis, Pharmaceutical industry, Research

THOUSAND OAKS, Calif., Oct. 20, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the global Phase 2 DeLLphi-301 study, evaluating tarlatamab, an investigational delta-like ligand 3 (DLL3) targeting BiTE® (bispecific T-cell engager) molecule, in patients with advanced stage small cell lung cancer (SCLC) who had failed two or more prior lines of treatment. The data are being presented today at 3:20 PM CEST at a Proffered Paper session as a late-breaking oral presentation (LBA92) during the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, with publication in the New England Journal of Medicine.

Key Points: 
  • THOUSAND OAKS, Calif., Oct. 20, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the global Phase 2 DeLLphi-301 study, evaluating tarlatamab, an investigational delta-like ligand 3 (DLL3) targeting BiTE® (bispecific T-cell engager) molecule, in patients with advanced stage small cell lung cancer (SCLC) who had failed two or more prior lines of treatment.
  • Of the patients who responded to treatment with tarlatamab at 10 mg dose, 58% experienced at least six months of response and 55% of responses were ongoing at data cutoff.
  • "Small cell lung cancer has represented one of the greatest challenges in cancer treatment, where there has been little progress against this deadly tumor type in decades," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.
  • "The tarlatamab results show the potential for this BiTE® molecule in a common solid tumor.